Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 13/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | NPC1 | O15118 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.57 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.57 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | F13A1 | P00488 | 1/20 | 0.54 |
| ▸ | TGM2 | P21980 | 1/20 | 0.54 |
| ▸ | TGM1 | P22735 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4913258 | 0.95 | GRIN2B (0.64) | GRIN2BCYP2D6CYP2C9SMN1; SMN2NPC1 | |
| SCHEMBL31210641 | 0.88 | SMN1; SMN2 (0.54) | GRIN2BCYP2D6CYP2C9SMN1; SMN2NPC1 | |
| SCHEMBL31714072 | 0.88 | GRIN2B (0.56) | GRIN2BCYP2D6CYP2C9SMN1; SMN2NPC1 | |
| SCHEMBL30492326 | 0.88 | GRIN2B (0.58) | GRIN2BCYP2D6CYP2C9SMN1; SMN2NPC1 | |
| SCHEMBL30228590 | 0.88 | GRIN2B (0.58) | GRIN2BCYP2D6CYP2C9SMN1; SMN2NPC1 | |
| SCHEMBL30492373 | 0.88 | GRIN2B (0.58) | GRIN2BCYP2D6CYP2C9SMN1; SMN2NPC1 | |
| SCHEMBL4286977 | 0.86 | GRIN2B (0.69) | GRIN2BCYP2D6CYP2C9SMN1; SMN2NPC1 | |
| SCHEMBL10153811 | 0.86 | GRIN2B (0.69) | GRIN2BCYP2D6CYP2C9SMN1; SMN2NPC1 | |
| SCHEMBL30625217 | 0.86 | GRIN2B (0.69) | GRIN2BCYP2D6CYP2C9SMN1; SMN2NPC1 | |
| SCHEMBL29532829 | 0.85 | GRIN2B (0.67) | GRIN2BCYP2D6CYP2C9SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1781661-B1 | VASOPRESSIN V1A ANTAGONISTS | VANTIA LTD (GB) | 2017-06-07 | — | — | EP | disclosed |
| EP-1781661-B1 | VASOPRESSIN V1A ANTAGONISTS | VANTIA LTD (GB) | 2017-06-07 | — | — | EP | disclosed |
| US-8202858-B2 | Vasopressin V1a antagonists | VANTIA LIMITED (GB) | 2012-06-19 | — | — | US | disclosed |
| US-8202858-B2 | Vasopressin V1a antagonists | VANTIA LIMITED (GB) | 2012-06-19 | — | — | US | disclosed |
| US-8202858-B2 | Vasopressin V1a antagonists | VANTIA LIMITED (GB) | 2012-06-19 | — | — | US | disclosed |
| EP-2256119-B1 | Vasopressin V1a antagonists | VANTIA LTD (GB) | 2012-05-09 | — | — | EP | disclosed |
| EP-2256119-B1 | Vasopressin V1a antagonists | VANTIA LTD (GB) | 2012-05-09 | — | — | EP | disclosed |
| US-20120101082-A1 | VASOPRESSIN V1A ANTAGONISTS | BATT ANDRZEJ ROMAN (GB) | 2012-04-26 | — | — | US | disclosed |
| US-20120101082-A1 | VASOPRESSIN V1A ANTAGONISTS | BATT ANDRZEJ ROMAN (GB) | 2012-04-26 | — | — | US | disclosed |
| US-20120101082-A1 | VASOPRESSIN V1A ANTAGONISTS | BATT ANDRZEJ ROMAN (GB) | 2012-04-26 | — | — | US | disclosed |
| EP-2264037-A1 | Vasopressin v1a antagonists | Vantia Limited (GB) | 2010-12-22 | — | — | EP | disclosed |
| EP-2264037-A1 | Vasopressin v1a antagonists | Vantia Limited (GB) | 2010-12-22 | — | — | EP | disclosed |
| EP-2256119-A1 | Vasopressin V1a antagonists | Vantia Limited (GB) | 2010-12-01 | — | — | EP | disclosed |
| EP-2256119-A1 | Vasopressin V1a antagonists | Vantia Limited (GB) | 2010-12-01 | — | — | EP | disclosed |
| US-20090029965-A1 | Vasopressin V1a Antagonists | FERRING B.V. (NL) | 2009-01-29 | — | — | US | disclosed |
| US-20090029965-A1 | Vasopressin V1a Antagonists | FERRING B.V. (NL) | 2009-01-29 | — | — | US | disclosed |
| US-20090029965-A1 | Vasopressin V1a Antagonists | FERRING B.V. (NL) | 2009-01-29 | — | — | US | disclosed |
| EP-1781661-A2 | VASOPRESSIN V1A ANTAGONISTS | Ferring B.V. (NL) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006021213-A2 | VASOPRESSIN V1A ANTAGONISTS | FERRING B.V. (NL) | 2006-03-02 | — | — | WO | disclosed |
| WO-2006021213-A2 | VASOPRESSIN V1A ANTAGONISTS | FERRING B.V. (NL) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101082-A1 | VASOPRESSIN V1A ANTAGONISTS | AVPR1A, AVPR2, AVPR1B | GRIN2B 1167/4885CYP2D6 1173/4885CYP2C9 2146/4885 |
| US-20090029965-A1 | Vasopressin V1a Antagonists | AVPR1A, AVPR2, AVPR1B | GRIN2B 1167/4885CYP2D6 1173/4885CYP2C9 2146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.